Accuthera

Accuthera is a clinical-stage biopharmaceutical company based in Tokyo, Japan, specializing in the development of innovative treatments for ophthalmic diseases. The company's primary focus is on ocular surface disorders, particularly Meibomian Gland Dysfunction (MGD) and dry eye syndrome. Its lead candidate, ACT-01, is a topical small molecule androgen receptor agonist designed to restore meibomian gland function and improve tear film stability. Accuthera aims to address significant unmet medical needs in the eye care market through targeted pharmacological interventions. The company leverages strategic partnerships and academic collaborations to advance its pipeline from discovery through clinical development.